The global Transfusion Diagnosis for Donor market size is predicted to grow from US$ 4402 million in 2025 to US$ 6479 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

The gross profit margin of major companies in the industry is between 50% 70%.

Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This includes mandatory screening for transfusion-transmitted infections (TTIs) such as HIV, Hepatitis B and C, and Syphilis using Nucleic Acid Testing (NAT) and ELISA. It also encompasses blood group serology (ABO/Rh typing) and cross-matching. These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.

The industrial chain begins upstream with providers of biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents. The midstream consists of manufacturers of automated blood screening platforms, molecular diagnostic systems, and immunoassays. Downstream applications include national and regional blood centers, hospital blood banks, and plasma collection stations. The chain is supported by cold-chain logistics providers and regulatory bodies. Service providers offer calibration, system maintenance, and integrated blood management software to track blood units from collection to clinical transfusion, ensuring full traceability and safety.

The market for transfusion diagnosis is witnessing a significant shift toward automated and molecular-based testing to minimize the window period of infection detection. Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies. A key trend is the integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity. Furthermore, the adoption of Big Data and AI in blood management systems is optimizing inventory and reducing wastage. While stringent regulatory requirements pose a high entry barrier, the expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities. Manufacturers are focusing on high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.

Infinity Market Research newest research report, the Transfusion Diagnosis for Donor Industry Forecast looks at past sales and reviews total world Transfusion Diagnosis for Donor sales in 2025, providing a comprehensive analysis by region and market sector of projected Transfusion Diagnosis for Donor sales for 2026 through 2032. With Transfusion Diagnosis for Donor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Transfusion Diagnosis for Donor industry.

This Insight Report provides a comprehensive analysis of the global Transfusion Diagnosis for Donor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Transfusion Diagnosis for Donor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Transfusion Diagnosis for Donor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Transfusion Diagnosis for Donor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Transfusion Diagnosis for Donor.

This report presents a comprehensive overview, market shares, and growth opportunities of Transfusion Diagnosis for Donor market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Instruments
    Kits and Reagents
    Segmentation by Diagnostic Purpose:
    Blood Grouping & Typing Diagnostics
    Infectious Disease Screening Diagnostics
    Segmentation by Testing Method:
    Immunoassay-Based Diagnostics
    Molecular Diagnostics

Segmentation by Application:

    Blood Banks
    Blood Donation/Transfusion Centers
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Grifols
    F. Hoffmann-La Roche
    Abbott
    Bio-Rad Laboratories
    Werfen
    QuidelOrtho Corporation
    AliveDx Holdings Finance
    BAG Diagnostics GmbH
    Diasorin
    Prestige Diagnostics
    Atlas Medical GmbH
    Lorne Laboratories